Hematopoietic stem cell transplantation in the treatment of lymphoma: reports from the 56th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2015.01.005
- VernacularTitle:造血干细胞移植治疗淋巴瘤:第56届美国血液学会年会报道
- Author:
Guangli YIN
;
Jianyong LI
;
Kourong MIU
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cell transplantation;
Lymphoma;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2015;24(1):13-16
- CountryChina
- Language:Chinese
-
Abstract:
The 56th American Society of Hematology (ASH) annual meeting has reported 171 abstracts about hematopoietic stem cell transplantation (HSCT) for treating lymphoma,including 102 autologous HSCT (auto-HSCT) and 69 allogeneic HSCT (allo-HSCT),which mainly covered clinical effects of HSCT on patients with relapse/refractory Hodgkin lymphoma and high risk,aggressive non-Hodgkin lymphoma,as well as the impact factors such as the best time for transplantation,improvement of conditioning regimen,applying target chemotherapy prior to transplantation,preventing graft-versus-host disease (GVHD),and predictors for transplantation outcome.
